Company Antibe Therapeutics Inc.
Equities
ATE
CA0370255097
Biotechnology & Medical Research
Business Summary
Number of employees: 11
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 15-12-31 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-05-05 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 12-10-31 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 20-11-23 | |
Amal Khouri
BRD | Director/Board Member | - | 18-03-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 53,009,362 | 48,481,043 ( 91.46 %) | 0 | 91.46 % |
Company contact information
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.com![address Antibe Therapeutics Inc.(ATE)](https://cdn.zonebourse.com/static/address/22293396.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |